Tumor Response Predicts Survival Time of Nivolumab Monotherapy for Advanced Gastric Cancer: A Subgroup Analysis of the DELIVER Trial (JACCRO GC-08).

Yu SunakawaYasuhiro SakamotoRyohei KawabataAtsushi IshiguroYusuke AkamaruYosuke KitoMasazumi TakahashiJin MatsuyamaHiroshi YabusakiAkitaka MakiyamaTakahisa SuzukiMasahiro TsudaHisateru YasuiJun HiharaAtsushi TakenoEisuke InoueWataru IchikawaMasashi Fujii

Published in: The oncologist (2024)

The final analysis confirmed the efficacy of nivolumab monotherapy for patients with advanced GC in routine clinical practice. The exploratory analysis indicated that increasing DpR was associated with longer median PFS and OS in nivolumab treatment at a later-line setting.

Keyphrases

clinical practice
combination therapy
open label
clinical trial
phase iii
study protocol
neoadjuvant chemotherapy
mass spectrometry
radiation therapy
lymph node
rectal cancer
high resolution